Business Context and Reporting Period
Lisata Therapeutics, Inc. (LSTA) filed a Form 8-K on January 27, 2026, reporting a material event that occurred on January 23, 2026. The company is a Delaware corporation with principal executive offices in Basking Ridge, NJ, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the termination of a specific commercial agreement.
Material Changes
On January 23, 2026, Lisata Therapeutics entered into a Mutual Termination Agreement with Qilu Pharmaceutical Co., Ltd. ("Qilu"). This agreement terminated the Exclusive License and Collaboration Agreement originally dated February 11, 2021, regarding the research, development, and commercialization of certepetide (formerly CEND-1) in the Greater China territory.
- Terminated Rights: Qilu's exclusive license for certepetide in Greater China (Mainland China, Hong Kong, Macau, and Taiwan) is no longer in effect.
- Lost Potential Revenue: The terminated agreement had provided the Company with eligibility for up to $200 million in development and commercial milestone payments and royalties ranging from 10% to 15% on licensed product sales.
- Surviving Obligations: The termination does not relieve parties of obligations that accrued prior to January 23, 2026, or provisions expressly indicated to survive.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or a discussion of general risk factors beyond the specific event reported. The primary contingency noted is the cessation of future potential milestone and royalty income from the Greater China region for certepetide under the Qilu agreement.
Investor Verification Checklist
- Verify the financial impact of the termination on the company's projected revenue stream, specifically the loss of the potential $200 million in milestones.
- Confirm whether any accrued but unpaid milestone payments or royalties from Qilu prior to January 23, 2026, are still receivable.
- Assess the company's strategy for certepetide commercialization in Greater China following the loss of the exclusive partner.
- Review subsequent filings for any new partnership agreements intended to replace the terminated Qilu collaboration.